Heroin Dependence Clinical Trial
Official title:
University of Houston Drug Abuse Research Development Program II
The study is examining the impact of a Virtual Reality Cue Exposure Therapy intervention on heroin cravings compared to Relapse Prevention Drug Education.
Injection Drug Use (IDU) is a chronic, relapsing condition with grave individual and public
health consequences.19-21 A majority (53%) of all past-year IDUs prefer heroin, as do 39% of
single-drug injectors, second only to Methamphetamine.22,23 Non-injection heroin use (NIDU)
is increasing, due to growing awareness of IDU risks, particularly HIV/AIDS;21,24-26
increased purity of street heroin;27-29 greater regulation of other opiates;30,31 and opioid
abusers switching to heroin for its lower cost.32 Many NIDUs transition to IDU, incurring
greater risks.2,21,33,34 Drug cravings are intense urges to use drugs35,36 and they
contribute to drug use37, relapse38, and transitioning from NIDU to IDU.39 Cravings are
triggered by environmental factors and due to the significance of craving in drug use and
relapse they will be part of the proposed criteria for DSM5.40,41
HIV, Hepatitis C (HCV), and Sexually-Transmitted Infections (STIs) continue to be associated
with both IDU and NIDU.33,42-44 Hispanics are over-represented among both IDU and NIDU heroin
users.21,23,45,46 Mexican American IDUs have very low rates of HIV.10,47 However, their HCV
rates are very high and continue to increase, further compromising their health.10,48,49 They
also have elevated rates of high-risk sex behaviors 33,50 and they are less likely to
decrease these high-risk sex behaviors than they are to decrease their injection- behavior
risks, especially as they age.10,51 Furthermore, HIV/HCV/STI prevention interventions can
lead to fatigue52-54 so they must continue to be delivered to at-risk populations across all
relevant settings. Young Texans ages 15-24 are becoming HIV infected at high rates, with
Hispanics disproportionately impacted and diagnosed later: 42% of infected Texan Hispanics
receive an HIV-positive and an AIDS diagnosis within the same year, compared to 32% of Anglos
and 31% of Blacks.55 Thus, early detection of high-risk Hispanics is vital, making this
proposal timely and critical.
Greatly needed are novel interventions that address drug cravings (DCs), take into account
environmental context, and incorporate HIV/HCV prevention components. Developing these
interventions and adapting them to the many diverse at-risk populations, however, can be
costly and challenging. Cue exposure therapy (CET)56,57 may be a viable approach. CET is a
promising intervention that can decrease DCs by repeatedly exposing an individual to a
craving inducing stimulus (e.g., a shooting gallery scenario) while simultaneously preventing
the conditioned behavioral response (e.g., drug use). The individual can be trained in vitro
(in the lab) to use coping skills in direct response to activated cravings, then use these
skills in vivo (in the natural environment). A challenge associated with CET, for both
ethical and logistical reasons, is the ability to expose individuals to realistic simulated
cues of the natural environment in a secure laboratory or therapeutic setting. Virtual
Reality (VR) is an innovative, cutting-edge tool that can enable researchers to overcome
these obstacles. VR scenarios integrate elements from the individual's various
contexts—culture, neighborhood, family, networks, and individual characteristics—into the
clinical or lab setting, and provide complex multi-sensory cues through an immersive
human-computer interaction.58
The public health significance of this primary project is high. Drug use in general and
injection drug use (IDU) in particular are serious public health concerns, as are the rates
of HCV and STIs in IDUs. Interventions that decrease craving, increase coping skills, and
incorporate HIV/HCV/STI prevention components can be critical tools in treating drug use
disorders and their serious health consequences. In addition, it is critical to train diverse
researchers who possess intimate knowledge of the populations impacted by drug use and who
understand the cultural and contextual elements of those populations, to conduct this
innovative research.
The specific research hypotheses and objectives are as follows:
1. Refine and develop a Virtual Reality Heroin Scenario (VRHS) using qualitative data
(i.e., photos and descriptions of heroin using sites and contexts) from our current
UHDARDP's Primary Project.
2. Measure the effects of exposure to virtual reality heroin cues on craving and
physiological reactivity.
Hypothesis 1a: VR cues will increase subjective heroin craving and physiological
reactivity.
Hypothesis 1b: Heroin craving and physiological reactivity will decrease as a result of
repeated exposure to virtual cues.
3. Compare Virtual Reality-Based Cue Exposure Therapy (VRCET) and Relapse Prevention Drug
Education (RPDE) on extinction of heroin craving and physiological reactivity across cue
trials.
Hypothesis 2: VRCET will attenuate cue-elicited subjective heroin craving and
physiological reactivity relative to RPDE.
4. Examine the in vivo effects of VRCET on heroin craving, craving coping skills, and
actual heroin use, compared to RPDE.
Hypothesis 3: VRCET will lead to a decrease in heroin craving, an increase in craving
coping skills use, and decreased heroin use, in the natural environment, compared to
RPDE.
5. Deliver an HIV/HCV prevention intervention to this high-risk population. Hypothesis 4:
The prevention intervention will increase prevention knowledge and intention to use the
skills learned.
6. Determine if medication assisted therapies, such as methadone or buprenorphine, have an
impact on cue reactivity for former heroin IDU when immersed in the virtual
environments, as compared to current users.
Hypothesis 5: Participants on medication assisted therapies will exhibit lower levels of cue
reactivity within the VR environment than participants who are currently still using heroin.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00577408 -
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
|
Phase 3 | |
Completed |
NCT00218309 -
Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
|
Phase 2 | |
Completed |
NCT00000210 -
Treatment Efficacy for Drug Abuse and AIDS Prevention - 1
|
Phase 2 | |
Completed |
NCT00000211 -
Treatment Efficacy for Drug Abuse and AIDS Prevention - 2
|
Phase 2 | |
Completed |
NCT02324725 -
Biomarkers of Injectable Extended Release Naltrexone Treatment
|
Phase 4 | |
Withdrawn |
NCT00000330 -
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5
|
Phase 2 | |
Completed |
NCT00249457 -
Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2
|
N/A | |
Completed |
NCT00218127 -
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
|
Phase 2 | |
Completed |
NCT04133974 -
Methadone Induced Memory Retrieval-extinction Procedure in Heroin Addicts
|
N/A | |
Completed |
NCT00015288 -
Buprenorphine and Naloxone Combination Study - 10
|
Phase 1 | |
Terminated |
NCT03711318 -
Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals
|
Phase 3 | |
Recruiting |
NCT02541526 -
Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia
|
Phase 3 | |
Active, not recruiting |
NCT02541513 -
An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence
|
Phase 3 | |
Completed |
NCT01760473 -
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
|
Phase 3 | |
Terminated |
NCT01395797 -
Pioglitazone for Heroin and for Nicotine Dependence
|
Phase 1/Phase 2 | |
Completed |
NCT01668706 -
Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts
|
N/A | |
Active, not recruiting |
NCT00609089 -
Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction
|
Phase 1/Phase 2 | |
Completed |
NCT00684840 -
Effects of Stress and Other Factors on Opiate Drug Choice.
|
N/A | |
Completed |
NCT00759005 -
Effect of Stress on Heroin-Related Memory Retrieval
|
N/A | |
Completed |
NCT00218530 -
Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1
|
Phase 1 |